Navigation Links
IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
Date:3/20/2008

quality of life."

Study background

The compassionate access study is being conducted initially at M. D. Anderson and Memorial-Sloan Kettering Cancer Center in New York. Eligible patients will have a confirmed diagnosis of high grade osteosarcoma with relapsed or recurrent disease, locally or metastatic, with resectable or not completely resectable disease, or who are unable to complete recommended chemotherapy due to toxicity.

Patients enrolled in the study will receive L-MTP-PE over one hour two times a week, at least three days apart, for 12 weeks (3 months). Patients will then receive L-MTP-PE once a week for the next 24 weeks (6 months). Additionally, patients may receive other treatments in combination with L-MTP-PE.

In addition to providing access to the drug, the objectives of the study are to provide supplemental safety and tolerability data for L-MTP-PE and supplemental pharmacokinetic information in a small patient subset.

For more information about the study please visit http://www.clinicaltrials.gov.

Update on L-MTP-PE Regulatory Status

The Company recently announced that following presentation of data at an oral explanation hearing before the Committee for Medicinal Products for Human Use (CHMP), the CHMP determined in a non-binding opinion that L-MTPE-PE suggested a possible clinical benefit in terms of survival and granted the Company a clock stop, or time extension. The clock stop will allow the Company additional time to respond to all the remaining questions regarding the marketing authorization application for L-MTP-PE (MAA). The CHMP has requested clarification of the existing data in order to gain assurance about the quality of the data before drawing any final conclusions from the data presented. In addition, the Company is required to address a number of remaining questions relating to chemistry, manufacturing and controls (CMC). The Comp
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
2. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
3. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
4. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
5. Access Pharmaceuticals to Conduct Conference Call to Update Financial Community
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
8. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
9. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
10. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
11. Pharmatech Teams up With Systems Medicine LLC and the Sarcoma Foundation of America for a Phase II Myxoid Liposarcoma Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- According to a new market research ... Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, ... - Global Forecasts to 2019 ", published by MarketsandMarkets, the ... Billion by 2019 with a CAGR of around 10.3% ... Browse   90   ma rket data ...
(Date:3/27/2015)... 27, 2015   Hospira, Inc. (NYSE: ... and the world,s leading provider of injectable drugs ... an evaluation of biosimilarity of its proposed biosimilar, ... Administration (FDA) conditionally approved name of RETACRIT™, compared ... These study data were presented at the National ...
(Date:3/27/2015)... March 27, 2015 RnRMarketResearch.com ... therapeutic market research report of 52 pages with ... business intelligence library. The report "Visceral ... the therapeutic development for Visceral Pain, complete with ... drug target, mechanism of action (MoA), route of ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... May 7, 2012 A new analysis concludes that rituximab, ... treatment responses lasting at least five years in approximately one ... of bleeding due to chronic immune thrombocytopenic purpura (ITP). In ... Blood , the Journal of the American Society ...
... Mass., May 7, 2012  CardioFocus, Inc., developer of ... treatment of atrial fibrillation (AF), announces that its ... the scientific sessions and during a private academic ... Society,s 33rd Annual Scientific Sessions, May 9-12 in ...
Cached Medicine Technology:Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 2Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets 3Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012 2Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012 3
(Date:3/28/2015)... 28, 2015 Coffee could not only perk ... you from gum disease, researchers have found. , They found ... , Coffee contains antioxidants. Antioxidants fight gum disease. Does coffee, ... at Boston Univ. Henry M. Goldman School of Dental Medicine ... 2014 issue of the Journal of Periodontology. , “This is ...
(Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
(Date:3/28/2015)... India Network visitor health insurance announced ... visitors who purchase the plan before arrival in the ... purchase the insurance program as soon as travel plans ... pre-existing medical conditions. Parents and grandparents traveling from India ... serious consequences to their health. Many visitors may not ...
(Date:3/28/2015)... 28, 2015 One in three young ... research presented today at the American Orthopaedic Society for ... examined the long term success of surgery for patients ... survey data from 242 patients who underwent ACL reconstruction ... Roe, MBBS, FRACS, from North Sydney Orthopaedic and Sports ...
(Date:3/28/2015)... 28, 2015 Genomic medicine experts have ... revealing, for the first time, key information for understanding ... read the newly posted story on the Surviving ... of British Columbia, the British Columbia Cancer Agency, and ... reveal underlying molecular alterations and mutations that can lead ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... 11 /PRNewswire/-- Temple University Hospital has,been ranked again ... respiratory,disorders by U.S. News & World Report in ... Hospital - home to the acclaimed Temple Lung ... across the country that were,evaluated in a range ...
... highest-rated Illinois hospital in six clinical,areas, CHICAGO, July ... specialties -- six of which make it the,highest-ranked in ... Report,s 2008,America,s Best Hospitals issue. This year, editorial staff ... and 170 were chosen and ranked according to the ...
... Nation,s 4th Best Hospital Overall, Placing 15 of its 16 ... Clinic Specialties Rated ... fourteenth year in a row,Cleveland Clinic,s cardiac care has been ranked ... World Report "America,s Best Hospitals",survey., The survey recognizes Cleveland Clinic ...
... HBO has acquired the pilot,"Fat Sells" co-created by ... Gren Wells. Academy Award winner Forest Whitaker ("The,Last King ... Broome on,this one-hour family drama set in the world ... Wells, who also has "Earthbound" set,up at The Film ...
... gave overwhelming, bipartisan,approval to legislation to avert cuts in ... circumstances,facing us, Jeffrey P. Harris, MD, FACP, president of ... We implore President Bush,to immediately sign this bill into ... in favor of H.R. 6331 are more than enough ...
... American Life League,applauds the members of the U.S. ... Parenthood on Wednesday evening., Calling it a "big ... Jim Jordan, Bill Sali, Mike Pence and six other,member ... an immediate cutoff of federal funding for it., ...
Cached Medicine News:Health News:Northwestern Memorial Among America's Best Hospitals in 10 Clinical Specialties According to U.S. News' 2008 Rankings 2Health News:Northwestern Memorial Among America's Best Hospitals in 10 Clinical Specialties According to U.S. News' 2008 Rankings 3Health News:For the 14th Year in a Row, Cleveland Clinic Heart Center Is Ranked No. 1 in U.S. News & World Report 'America's Best Hospitals' Survey 2Health News:For the 14th Year in a Row, Cleveland Clinic Heart Center Is Ranked No. 1 in U.S. News & World Report 'America's Best Hospitals' Survey 3Health News:Whitaker and Broome Get Wells 'Fat' at HBO 2Health News:ACP applauds Senate to vote to pass H.R. 6331 and avert physician payment cut 2Health News:American Life League Applauds Congressional Action Against Planned Parenthood 2
The Duracon system provides superb articular conformity throughout the range of motion, reducing contact stresses generally associated with wear....
Cruciate retaining, posterior stabilized and constrained components....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
... The TC-PLUS Solution tricompartmental total knee ... with knee arthroplasty. State-of-the-art design and manufacturing ... achieve optimum biomechanical function as well as ... polyethylene tibial insert to keep wear to ...
Medicine Products: